The invention relates to a
Sorafenib sustained-release
implant for treating a
solid tumor, which is characterized in that: the sustained-release
implant contains an effective anticancer amount of
Sorafenib and sustained-release excipients and a certain amount of sustained-release regulators. The
solid tumors comprise the esophageal canner, the gastric canner, the breast canner, the ovarian canner, the
prostate canner, the bladder canner, the liver canner, the
lung canner, and the
rectum canner. The sustained-release excipients are mainly a
copolymer of
glycollic acid and hydroxyacetic acid and one of the two materials, polifeprosan and poly-(L-
lactide-co-
ethyl phosphonate), or a combination of the two materials, in the process of the degradation and absorption of which the
Sorafenib is continuously released to part of the tumor, thus the entire
toxicity of the Sorafenib is significantly reduced while an effective
medicine consistency is maintained on part of the tumor. That the sustained-release
implant is implanted inside part of the tumor can not only reduce the entire
toxicity of the Sorafenib but also enhance the
medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as
chemotherapeutic drugs and radiotherapy.